Skip to main content
Top
Published in: Arthritis Research & Therapy 1/2012

Open Access 01-12-2012 | Oral presentation

Regulation of inflammatory immune responses leading to the development of bone destructive autoimmune disease rheumatoid arthritis by IL-27

Authors: Takayuki Yoshimoto, Mingli Xu, Izuru Mizuguchi, Yukino Chiba, Sadahiro Kamiya, Masanori Matsui, Shiva Shahrara, Junichiro Mizuguchi

Published in: Arthritis Research & Therapy | Special Issue 1/2012

Login to get access

Excerpt

IL-27, a member of the IL-6/IL-12 family of cytokines, induces early helper T (Th)1 differentiation and generation of cytotoxic T cells and IL-10-producing type 1 regulatory T cells, while it suppresses the production of inflammatory cytokines and inhibits Th2 and Th17 differentiation [1, 2]. The receptor activator of NF-kB ligand (RANKL), which is expressed by not only osteoblasts but also activated T cells, plays an important role in bone-destructive disease rheumatoid arthritis (RA). Recently, IL-17-producing Th17 cells were identified as the exclusive osteoclastogenic T-cell subset. This is because Th17 cells express RANKL, and that IL-17 not only induces RANKL expression on osteoblasts, but also increases the production of various inflammatory molecules. It was previously reported that IL-27 is detected in RA synovial membranes and that treatment with IL-27 attenuated inflammatory responses in collagen-induced arthritis (CIA), one of mouse RA models. …
Literature
1.
go back to reference Yoshimoto T, Morishima N, Okumura M, Chiba Y, Onishi K, Mizoguchi I, Mizuguchi J: Interleukin-27: biological properties and application to immunotherapy of cancer. Trends Cancer Res. 2008, 4: 93-103. Yoshimoto T, Morishima N, Okumura M, Chiba Y, Onishi K, Mizoguchi I, Mizuguchi J: Interleukin-27: biological properties and application to immunotherapy of cancer. Trends Cancer Res. 2008, 4: 93-103.
2.
go back to reference Morishima N, Mizoguchi I, Okumura M, Chiba Y, Xu M, Shimizu M, Matsui M, Mizuguchi J, Yoshimoto T: A pivotal role for interleukin-27 in CD8+T cell functions and generation of cytotoxic T lymphocytes. J Biomed Biotechnol. 2010, 2010: 605483-PubMedCentralCrossRefPubMed Morishima N, Mizoguchi I, Okumura M, Chiba Y, Xu M, Shimizu M, Matsui M, Mizuguchi J, Yoshimoto T: A pivotal role for interleukin-27 in CD8+T cell functions and generation of cytotoxic T lymphocytes. J Biomed Biotechnol. 2010, 2010: 605483-PubMedCentralCrossRefPubMed
3.
go back to reference Kamiya S, Nakamura C, Fukawa T, Ono K, Ohwaki T, Yoshimoto T, Wada S: Effects of IL-23 and IL-27 on osteoblasts and osteoclasts: inhibitory effects on osteoclast differentiation. J Bone Miner Metab. 2007, 25: 277-285. 10.1007/s00774-007-0766-8.CrossRefPubMed Kamiya S, Nakamura C, Fukawa T, Ono K, Ohwaki T, Yoshimoto T, Wada S: Effects of IL-23 and IL-27 on osteoblasts and osteoclasts: inhibitory effects on osteoclast differentiation. J Bone Miner Metab. 2007, 25: 277-285. 10.1007/s00774-007-0766-8.CrossRefPubMed
4.
go back to reference Pickens SR, Volin MV, Mandelin AM, Matsui M, Yoshimoto T, Shahrara S: Local expression of IL-27 ameliorates collagen induced arthritis. Arthritis Rheum. Pickens SR, Volin MV, Mandelin AM, Matsui M, Yoshimoto T, Shahrara S: Local expression of IL-27 ameliorates collagen induced arthritis. Arthritis Rheum.
5.
go back to reference Kamiya S, Okumura M, Chiba Y, Fukawa T, Nakamura C, Nimura N, Mizuguchi J, Wada S, Yoshimoto T: IL-27 suppresses RANKL expression in CD4+T cells in part through STAT3. Immunol Lett. 2011, 138: 47-53. 10.1016/j.imlet.2011.02.022.CrossRefPubMed Kamiya S, Okumura M, Chiba Y, Fukawa T, Nakamura C, Nimura N, Mizuguchi J, Wada S, Yoshimoto T: IL-27 suppresses RANKL expression in CD4+T cells in part through STAT3. Immunol Lett. 2011, 138: 47-53. 10.1016/j.imlet.2011.02.022.CrossRefPubMed
Metadata
Title
Regulation of inflammatory immune responses leading to the development of bone destructive autoimmune disease rheumatoid arthritis by IL-27
Authors
Takayuki Yoshimoto
Mingli Xu
Izuru Mizuguchi
Yukino Chiba
Sadahiro Kamiya
Masanori Matsui
Shiva Shahrara
Junichiro Mizuguchi
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue Special Issue 1/2012
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar3576

Other articles of this Special Issue 1/2012

Arthritis Research & Therapy 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.